Esophageal Cancer
Conditions
Keywords
squamous cell carcinoma of the esophagus, stage IIA esophageal cancer, stage IIB esophageal cancer, stage IIIA esophageal cancer, stage IIIB esophageal cancer, stage IIIC esophageal cancer
Brief summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cetuximab, chemotherapy, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase I/II trial is studying the side effects and best dose of oxaliplatin and fluorouracil when given together with cetuximab and radiation therapy and to see how well they work in treating patients with stage II or stage III esophageal cancer.
Detailed description
OBJECTIVES: Primary * Determine the maximum tolerated dose of oxaliplatin and fluorouracil when administered with cetuximab and radiotherapy in patients with stage II or III squamous cell carcinoma of the esophagus. (Phase I) * Determine the response rate in patients treated with this regimen. (Phase II) Secondary * Determine the toxicity of this regimen in these patients. * Determine the postoperative complication rate and lethality in patients treated with this regimen. * Determine the R0 resection rate in patients treated with this regimen. * Determine the overall survival of patients treated with this regimen. * Determine the event-free survival of patients treated with this regimen. * Determine the metabolic response rate in patients treated with this regimen. OUTLINE: This is a phase I, dose-escalation study of oxaliplatin and fluorouracil followed by an open-label, phase II study. * Phase I: Patients receive cetuximab IV over 60-90 minutes on days -15, -8, 1, 8, 15, 22, and 29; oxaliplatin IV over 120 minutes on days 1, 8, 22, and 29; and fluorouracil IV continuously on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients then undergo radical esophagectomy 29-42 days after the completion of chemoradiotherapy. Cohorts of 3-6 patients receive escalating doses of oxaliplatin and fluorouracil until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. * Phase II: Patients receive oxaliplatin and fluorouracil as in phase I at the MTD determined in phase I. Patients also receive cetuximab and undergo radiotherapy and radical esophagectomy as in phase I. After completion of study therapy, patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 43 patients will be accrued for this study.
Interventions
BIOLOGICALcetuximab
DRUGfluorouracil
DRUGoxaliplatin
PROCEDUREconventional surgery
PROCEDUREneoadjuvant therapy
RADIATIONradiation therapy
Sponsors
Technical University of Munich
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed squamous cell carcinoma of the esophagus, meeting the following criteria: * Locally advanced disease (T3-T4, N0-N+ \[T2, N0 for cervical esophageal carcinoma\]) * Potentially resectable disease * No distant metastases (M1b) * No tumor infiltration of the tracheobronchial system * Bartels preoperative risk analysis \< 22 PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-1 or Karnofsky PS 70-100% * Creatinine ≤ 1.5 mg/dL OR creatinine clearance \> 60 mL/min * Bilirubin ≤ 1.5 mg/dL * ALT and AST ≤ 2 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 2 times ULN * WBC ≥ 3,000/mm³ * Granulocyte count ≥ 2,000/mm³ * Platelet count ≥ 100,000/mm³ * No pre-existing polyneuropathy \> grade 1 * No active uncontrolled infection * PaO\_2 ≥ 60 mm Hg on room air * FEV\_1 ≥ 60% of normal * No New York Heart Association class II-IV cardiac insufficiency * Ejection fraction ≥ 35% * No angina pectoris (at rest or under stress) unexplained by interventional cardiology * No myocardial infarction within the past 6 months * No histologically confirmed liver cirrhosis * No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanomatous skin cancer * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: * No prior chemotherapy * No prior radiotherapy to the thorax region * No current esophageal stent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose of oxaliplatin and fluorouracil (Phase I) | — |
| Response rate (histological remission) (Phase II) | — |
Secondary
| Measure | Time frame |
|---|---|
| R0 resection rate | — |
| Overall survival | — |
| Toxicity as measured by NCI-CTC criteria | — |
| Metabolic response rate | — |
| Event-free survival | — |
| Postoperative complication rate and lethality | — |
Countries
Germany
Outcome results
None listed